Senti Bio to Present at the 2025 Synthetic Biology: Engineering, Evolution, & Design (SEED) Conference
Senti Biosciences (Nasdaq: SNTI), a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies, will present at the 2025 SEED Conference in Houston, TX. The company's Co-Founder and CEO, Timothy Lu, MD, PhD, will deliver a presentation titled "Solving the Grand Challenge of Tumor-Specific Therapies with Logic-Gated Cells" on June 24, 2025 at 1:20 PM CT.
The SEED Conference, established in 2014, is a premier technical event for synthetic biology professionals that has attracted over 5,000 attendees since its inception. The conference serves as a platform for sharing research, networking, and discussing advances in synthetic biology.
Senti Biosciences (Nasdaq: SNTI), un'azienda biotecnologica in fase clinica focalizzata sullo sviluppo di terapie cellulari e geniche di nuova generazione, presenterà al 2025 SEED Conference a Houston, TX. Il cofondatore e CEO dell'azienda, Timothy Lu, MD, PhD, terrà una presentazione intitolata "Risolvere la grande sfida delle terapie tumorali specifiche con cellule a logica controllata" il 24 giugno 2025 alle 13:20 CT.
La SEED Conference, fondata nel 2014, è un evento tecnico di riferimento per i professionisti della biologia sintetica che ha attirato oltre 5.000 partecipanti dalla sua nascita. La conferenza rappresenta una piattaforma per condividere ricerche, fare networking e discutere i progressi nella biologia sintetica.
Senti Biosciences (Nasdaq: SNTI), una empresa biotecnológica en etapa clínica centrada en el desarrollo de terapias celulares y génicas de próxima generación, presentará en la Conferencia SEED 2025 en Houston, TX. El cofundador y CEO de la compañía, Timothy Lu, MD, PhD, ofrecerá una presentación titulada "Resolviendo el gran desafío de las terapias específicas para tumores con células con compuertas lógicas" el 24 de junio de 2025 a la 1:20 PM CT.
La Conferencia SEED, establecida en 2014, es un evento técnico de primer nivel para profesionales de la biología sintética que ha atraído a más de 5,000 asistentes desde su inicio. La conferencia sirve como plataforma para compartir investigaciones, establecer contactos y discutir avances en biología sintética.
Senti Biosciences (Nasdaq: SNTI)는 차세대 세포 및 유전자 치료제 개발에 주력하는 임상 단계 생명공학 기업으로, 텍사스 휴스턴에서 열리는 2025 SEED 컨퍼런스에서 발표할 예정입니다. 회사의 공동 창립자 겸 CEO인 Timothy Lu, MD, PhD가 2025년 6월 24일 오후 1시 20분 CT에 "논리 게이트 세포를 활용한 종양 특이적 치료제의 대과제 해결"이라는 제목으로 발표를 진행합니다.
2014년에 설립된 SEED 컨퍼런스는 합성 생물학 전문가들을 위한 주요 기술 행사로, 지금까지 5,000명 이상의 참가자를 유치했습니다. 이 컨퍼런스는 연구 공유, 네트워킹, 합성 생물학의 발전 논의를 위한 플랫폼 역할을 합니다.
Senti Biosciences (Nasdaq : SNTI), une entreprise biotechnologique en phase clinique spécialisée dans le développement de thérapies cellulaires et géniques de nouvelle génération, présentera lors de la conférence SEED 2025 à Houston, TX. Le cofondateur et PDG de la société, Timothy Lu, MD, PhD, donnera une présentation intitulée « Résoudre le grand défi des thérapies tumorales spécifiques avec des cellules à portes logiques » le 24 juin 2025 à 13h20 CT.
La conférence SEED, créée en 2014, est un événement technique de premier plan pour les professionnels de la biologie synthétique, ayant rassemblé plus de 5 000 participants depuis sa création. La conférence sert de plateforme pour partager des recherches, réseauter et discuter des avancées en biologie synthétique.
Senti Biosciences (Nasdaq: SNTI), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung der nächsten Generation von Zell- und Gentherapien spezialisiert hat, wird auf der 2025 SEED Konferenz in Houston, TX, präsentieren. Der Mitbegründer und CEO des Unternehmens, Timothy Lu, MD, PhD, wird am 24. Juni 2025 um 13:20 Uhr CT einen Vortrag mit dem Titel "Die große Herausforderung tumorspezifischer Therapien mit logisch gesteuerten Zellen lösen" halten.
Die SEED Konferenz, gegründet im Jahr 2014, ist eine führende technische Veranstaltung für Fachleute der synthetischen Biologie, die seit ihrer Gründung über 5.000 Teilnehmer angezogen hat. Die Konferenz dient als Plattform zum Austausch von Forschungsergebnissen, Networking und Diskussionen über Fortschritte in der synthetischen Biologie.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., June 24, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it will present at the 2025 Synthetic Biology: Engineering, Evolution, & Design (SEED) Conference being held June 23-26, 2025 in Houston, TX.
Details of the presentation are as follows:
Session: Building with Biology
Title: Solving the Grand Challenge of Tumor-Specific Therapies with Logic-Gated Cells
Presenter: Timothy Lu, MD, PhD, Co-Founder and CEO of Senti Biosciences
Date and Time: Tuesday, June 24, 2025 at 1:20 PM CT
The SEED Conference series, established in 2014, has secured its position as the premier technical event for synthetic biologists to present their work, network, and build meaningful relationships. Since its inception, SEED has drawn leaders and rising stars in the field, fostering collaboration and innovation. Each year, it provides an essential platform for sharing the latest research, discussing groundbreaking advances, and exploring the future applications of synthetic biology. With over 5,000 synthetic biologists and associated professionals attending since its launch, SEED has become a crucial gathering for those in the fields of bioengineering, biotechnology, and bioprocessing.
For more information about the 2025 SEED Conference, please visit synbioconference.org/2025.
About Senti Bio
Senti Bio is a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases. To achieve this, Senti Bio is leveraging its synthetic biology platform to engineer Gene Circuits into new medicines with enhanced precision and control. These Gene Circuits are designed to precisely kill cancer cells, to spare healthy cells, to increase specificity to target tissues, and/or to be controllable even after administration. The Company’s wholly-owned pipeline is comprised of cell therapies engineered with Gene Circuits to target challenging liquid and solid tumor indications. Senti’s Gene Circuits have been shown preclinically to work in both NK and T cells. Senti Bio has also preclinically demonstrated the potential breadth of Gene Circuits in other modalities and diseases outside of oncology, and continues to advance these capabilities through partnerships.
Availability of Other Information About Senti Biosciences, Inc.
For more information, please visit the Senti Bio website at www.sentibio.com or follow Senti Bio on X (@SentiBio) and LinkedIn (Senti Biosciences). Investors and others should note that we communicate with our investors and the public using our company website (www.sentibio.com), including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X and LinkedIn. The information that we post on our website or on X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
SNTI@jtcir.com
FAQ
When is Senti Biosciences (SNTI) presenting at the 2025 SEED Conference?
Who will be presenting for Senti Biosciences (SNTI) at the SEED Conference?
What is the topic of Senti Biosciences' (SNTI) presentation at SEED 2025?
What is the SEED Conference where Senti Biosciences (SNTI) is presenting?
